BioLineRx (BLRX) recently announced that BL-8040 has shown positive pre-clinical results for the treatment of thrombocytopenia (reduced platelet production). The data was published in the British Journal of Hematology.
The effect of repeated doses of BL-8040 on healthy and chemotherapy-induced thrombocytopenic mice was evaluated in the pre-clinical study.
The number of megakaryocytes within the bone marrow improved significantly with the repeated administration of BL-8040. Megakaryocytes are the cells that produce platelets.
Moreover, BL-8040 increased the number of hematopoietic progenitor cells both in the bone marrow and in the blood. These cells generate platelets as well as red and white blood cells. The severity and duration of chemotherapy-induced thrombocytopenia and cytopenia also declined significantly.
Thrombocytopenia is a frequent side effect of chemotherapy. The candidate’s ability to reduce thrombocytopenia makes it more attractive for the use of blood cancer treatment.
We remind investors that in Sep 2012, the rights to BL-8040 were in-licensed by the BioLineRxfrom Biokine Therapeutics Ltd.
BioLineRx’ BL-8040 is in a phase II study for the treatment of acute myeloid leukemia (:AML). The multicenter, open-label, phase II study will evaluate the safety and efficacy of repeated escalating doses of BL-8040 in adults suffering from relapsed/refractory AML. Primary endpoints include safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the candidate and an efficacy evaluation.
BioLineRx carries a Zacks Rank #3 (Hold). Currently, companies like Pharmacyclics, Inc. (PCYC), Questcor Pharmaceuticals Inc. (QCOR) and Anika Therapeutics Inc. (ANIK) look well-positioned with a Zacks Rank #1 (Strong Buy).
More From Zacks.com